This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Shua-Haim, J. R. Articles by Ross, J. S. Search for Related Content PubMed Articles by Shua-Haim, J. R. Articles by Ross, J. S. Social Bookmarking                         What's this?

Donepezil (Aricept®) treatment of multi infarct dementia: The caregivers and clinical impression

Outpatient Geriatric Department, Jersey Shore Medical Center, The Medical Center of Ocean County, Meridian Health System, and the Center of Aging at UMDNJ-SOM, Stratford, New Jersey

Vered Shua-Haim, RN, BSN

Alzheimer's Research Corporation, Senior Research Coordinator, ARC, Eatontown, New Jersey

Eric Comsti, MD

J. S. Ross, MD, FACP, AGSF, CMD

Outpatient Geriatric Department, Jersey Shore Medical Center, The Medical Center of Ocean County, Meridian Health System, and the Center of Aging at UMDNJ-SOM, Stratford, New Jersey

The purpose of this study was to investigate the clinical and caregivers impression of Aricept ^® treatment in patients suffering from Multi-Infarct Dementia (MID).

In a prospective study 73 MID patients1 were treated with Donepezil (Aricept®) for 16-to 20-weeks. Donepezil was administered as a 5mg tablet once daily at bedtime. After four weeks, patients tolerant of the 5-mg dose were increased to 10 mg daily. All patients satisfied the DSM-III-R criteria for Multi-Infarct Dementia.²After 16-to 20-weeks of treatment, the patient's caregiver completed a questionnaire concerning the effectiveness of the drug. Subjective cognitive improvement, MMSE,³ ADL4 and IADL5 outcomes were all assessed before and after treatment (referred to as Clinical Impression). Behavioral outcomes evaluated included depression, agitation, violence, anxiety, and paranoid thoughts. Functional and overall family satisfaction were also evaluated. Side effects as well as reasons for discontinuation from the study were also reported.

Seventy-three patients participated in the study. Twelve patients (16 percent) terminated participation due to side effects. Total adverse events were reported in 34 (46.5 percent) of patients. Cognitive improvement was reported in 31 (42.4 percent) patients. Verbal skills and attention were the most commonly reported cognitive improvement. Average MMSE declined by 2.6 points after 16-weeks of treatment. No behavioral improvement was reported. Behavioral deterioration was reported in 16 (21.9 percent) of patients. Functional improvement was reported in 32 (42.8 percent) patients. Overall positive family satisfaction was reported in 54 (73.9 percent) patients.

Although Donepezil treatment was approved by the FDA for the treatment of Alzheimer's Disease (AD), such treatment for MID patients appears to be a reasonably safe and effective treatment from the caregiver and family's point of view.

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 15, No. 4, 201-211 (2000)
DOI: 10.1177/153331750001500408


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?